1. Erythrocytes in control patients and in atherosclerosis patients seem to have a variable grade of affinity for adenosine and for plasma glucose. This variable grade seems to fix the level of the adenosine triphosphate (ATP) reserves and induces the erythrocytes' deformability.
2. The drop in the level of ATP reserves that induces the poor deformability of the erythrocytes in atherosclerosis patients would appear to be caused by two consecutive shortages: first a shortage that seems to be related to a deficiency of erythrocyte adenosine as the ATP shortage disappears with dipyridamole treatment and then a shortage induced by the lack of erythrocyte glucose and suppressed by the addition of ticlopidine to the dipyridamole treatment.
Get full access to this article
View all access options for this article.
References
1.
Solvay H., Kahn M., Cloarec M., et al: Platelet hyperaggregability, blood prostacyclin and effect of dipyridamole. Angiology37(3):175-184, 1986.
2.
Willems CH, Van Aken WG, Van Mourik JA: Binding of prostacyclin (PGI) to human erythrocytes. Acta Therapeutica6:31, 1980. 2+
3.
Schatzmann HJ : ATP-dependent Ca2+ extrusion from human red cells. Experientia22:364-368, 1966.
4.
Schatzmann HJ : The red cell calcium pump. Ann Rev Physiol45:303-312, 1983.
5.
Weed RI, La Celle PL, Merville W: Metabolic dependence of red cell deformability . J Clin Invest48:795-809, 1969.
6.
Schatzmann HJ , Vincenzi FF: Calcium movements across the membrane of human red cells. J Physiol201:369-395, 1969.
7.
Yoshihito Y. , Jacob HS, Matsumoto N., White J.: A possible role for cyclic nucleotides in the regulation of erythrocyte shape and permeability . J Lab Clin Med88:555-561, 1976.
8.
Szasz I., Hasitz M., Breuer JH, et al: Biconcave shape and its transformation in human red cells. Acta Biol Acad Sci Hung29:1-17, 1978.
9.
Roufogalis BP : Regulation of calcium translocation across the red cell membrane. Can J Physiol Pharmacol57:1331-1349, 1979.
10.
Sarkadi B.: Active calcium transport in human cells. Biochim et Biophysica Acta604:159-190, 1980.
11.
Schram E., Roosens H., De Baetselier P.: Luminescence meter for the kinetic measurement of phagocytic activity and other luminescent reactions. In: Analytical Applications of Bioluminescence and Chemiluminescence, ed. by Kricka LJ, Stanley PE, Thorpe GHG, Whitehead TP.Academic Press, 1984, pp 289-295.
12.
Roos H., Pleger K.: Kinetics of adenosine uptake by erythrocytes and the influence of dipyridamole . Mol Pharmacol8:417-425, 1972.
13.
Schrader J. , Berne RM, Rubio R.: Uptake and metabolism of adenosine by human, erythrocyte ghosts. Am J Physiol223:159-166, 1972.
14.
Dresse A., Chevolet C., Delapierre D., et al: Pharmacokinetics of oral dipyridamole and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol23:229, 1982.
15.
Sollevi A., Ostergen J., Hiemdahl P., et al: The effect of dipyridamole on plasma adenosine levels in skin microcirculation in man. J Clin ChemBiochem20:420, 1982.
16.
Fredholm BB : Are methylxanthine's effects due to antagonism of endogenous adenosine?Trends Pharmacol Sci1:129-132, 1980.
Widdas WF: The asymmetry of the hexose transfer system in the human red cell membrane . Curr Top Membr Transp14:165-223, 1980.
19.
Chaliss Jra , Taylor LP, Holman GD: Sugar transport asymmetry in human erythrocytes. The effect of bulk haemoglobin removal and the addition of methylxanthines . Acta Biochim Biophys602:155-166, 1980.
20.
Solvay H., Van Schepdael J: Evaluation clinique et biologique du traitement à long terme par le dipyridamole de 190 patients athéromateux. Ars Medici36:795-805, 1981.
21.
Solvay H., Kahn M., Selosse P., et al: Atherosclerosis and cerebral ischemic attacks: Intakes of cerebrography with xenon 133 inhaled and platelet tests in the diagnosis and clinical and therapeutic monitoring: The preventive role of dipyridamole. Angiology35(11):709-717, 1984.
22.
Briguglio F. , Buta V., Dimarco V., Circosta C.: Variazoni del contenuto di ATP eritrocitario per effeto della ticlopidina. Studio preliminare in sogetti normali. Recenti acquisizioni in tema di terapia antipiastrinica. Milano , Masson Italia Editori, 1982.
23.
Daveloose D. , Sablayrolles M., Molle D., Leterrier F.: Interaction of ticlopidine with the erythrocyte membrane. Biochem Pharmacol31:3949-3954, 1982.
24.
Lundin A., Rickardsson A., Thore A.: Continuous monitoring of ATP-converting reactions by purified firefly luciferase. AnalytBiochem75:611-620, 1976.
25.
Sablayrolles M., Wajcman H., Labie D.: International Symposium on Abnormal Haemoglobins. Genetics, Populations and Diseases. Jerusalem , September 6-11, 1981.
26.
Abou-Khalil S., Abou-Khalil WH, Yuris AA: Mechanism of interaction of ticlopidine and its analogues with the energy-conserving mechanism in mitochondria . Biochem Pharmacol38:1855-1859, 1986 .
27.
Lew VL, Tsien RY, Miller C.: The physiological (Ca2 +) level and pump-leak turnover in intact red cells measured with the use of an incorporated Ca-Chellato. Nature298:478-481, 1982.
28.
Richards DR , Rega AF, Garrahan SJ: Two classes of sites for ATP in the Ca2+ ATPase from human red cell membranes. Acta Biochim Biophys511:194-210, 1978.
29.
Muallem S., Karlisch Sjd: Studies of the mechanism of regulation of the red cell Ca2+ pump by calmodulin and ATP. Acta Biochim Biophys647:73-86, 1981.
30.
Garrahan PJ , Rega AF: Activation of partial reactions of the Ca2+ ATPase from human red cells by Mg and ATP. Acta Biochim Biophys513:59-65, 1978.
31.
Goldstein JL , Brown RS: The LDL receptor defect in familial hypercholesterolemia: Implications for pathogenis and therapy. Med Clin North Am66:335, 1982.
32.
Brown NS, Goldstein JL: How LDL receptors influence cholesterol and atherosclerosis. Sci Am1984, pp 251-258.
